Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02642393 · ClinicalTrials.gov registry record · Phase 3

Study of Urate Elevation in Parkinson's Disease, Phase 3

A Phase 3 study of Parkinson's Disease, sponsored by Michael Alan Schwarzschild.

Completed
Registry status
Phase 3
Development phase
298
Enrollment target
20
Study locations

NCT02642393 is a Phase 3 study of Parkinson's Disease that has completed, run by Michael Alan Schwarzschild. The registered enrollment target is 298 participants, below the 640-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (53% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02642393, a Phase 3 study of Parkinson's Disease, has completed, sponsored by Michael Alan Schwarzschild.

COMPLETED
Registry status
Phase 3
Development phase
298 participants
Enrollment target
20
Study locations

Study Summary

A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial to determine whether oral inosine dosed to moderately elevate serum urate (from ≤5.7 mg/dL to 7.1-8.0 mg/dL) over 2 years slows clinical decline in early PD. Clinical decline will be assessed as change in the primary outcome variable of the Movement Disorders Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), a composite scale comprising patient- and clinician-reported outcomes.

Conditions Studied

Parkinson's Disease

Interventions

  • DRUG Placebo
  • DRUG Inosine

Study Locations (20)

California

  • University of California San Diego - La Jolla
  • University of Southern California - Los Angeles
  • University of California Davis - Sacramento
  • University of California San Francisco - San Francisco

Arizona

  • Barrow Neurological Institute - Phoenix
  • Mayo Clinic Arizona - Scottsdale
  • Banner Sun Health Research Institute - Sun City

Illinois

  • Northwestern University - Chicago
  • Rush University Medical Center - Chicago
  • Neurosciences Institute at Central DuPage Hospital - Winfield

Colorado

  • University of Colorado - Aurora
  • Rocky Mountain Movement Disorder Center - Englewood

Georgia

  • Emory University - Atlanta
  • Augusta University - Augusta

Alabama

  • University of Alabama at Birmingham - Birmingham

Connecticut

  • Hartford HealthCare Movement Disorders Center - Vernon

Florida

  • University of South Florida - Tampa

Trial Details

FieldValue
Enrollment Target 298 participants
Start Date 2016-06
Est. Completion 2019-06
Phase Phase 3

Sponsor

Michael Alan Schwarzschild

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02642393

The ClinicalTrials.gov registry entry for NCT02642393 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 298 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 640-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (53% lower). The listed sponsor is Michael Alan Schwarzschild, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02642393 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Arizona, Illinois.

Frequently Asked Questions

What is clinical trial NCT02642393 about?

NCT02642393 is a clinical study titled "Study of Urate Elevation in Parkinson's Disease, Phase 3". A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial to determine whether oral inosine dosed to moderately elevate serum urate (from ≤5.7 mg/dL to 7.1-8.0 mg/dL) over 2 years slows clinical decline in early PD. Clinical decline will be assessed as change in the primary outcome...

What is the current status of trial NCT02642393?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 298 participants. The study started on 2016-06. Estimated completion is 2019-06.

What conditions does trial NCT02642393 study?

This clinical trial studies the following conditions: Parkinson's Disease.

What interventions are being tested in trial NCT02642393?

The interventions under investigation include: Placebo (DRUG), Inosine (DRUG).

Who is sponsoring clinical trial NCT02642393?

This trial is sponsored by Michael Alan Schwarzschild, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02642393 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Parkinson's Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Parkinson's Disease

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.